Payment overview · 2025
General Payments
$1,040.43
48 reported records · 14 companies
Healthcare provider profile · identity verified
Daniel Kwon, DO
Allopathic & Osteopathic Physicians|Family Medicine|Geriatric Medicine · PARAMOUNT, CA · NPI 1639736846
Verified facts
What the public records show
CMS Open Payments records show Daniel Kwon, DO received $1,040.43 in general payments during 2025 across 48 reported records.
Ardelyx, Inc. accounted for 17.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Gemtesa, Jardiance, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Ozempic by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $184.30 | 17.7% | 7 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $165.65 | 15.9% | 10 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $152.74 | 14.7% | 7 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $98.18 | 9.4% | 5 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $82.56 | 7.9% | 3 | 2025 |
| VIVUS LLC | Unresolved — no canonical attribution shown | $72.20 | 6.9% | 3 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $53.01 | 5.1% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $50.38 | 4.8% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $50.33 | 4.8% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $39.31 | 3.8% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $34.19 | 3.3% | 2 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $21.37 | 2.0% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $19.34 | 1.9% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $16.87 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,040.43 | 48 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $184.30 | 7 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $165.65 | 10 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $152.74 | 7 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $82.56 | 3 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $82.56 | 3 | 2025 |
Source payment records
|
|||||
| PANCREAZE Normalized: pancreaze |
Drug | VIVUS LLC | $72.20 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $63.54 | 3 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $53.01 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $50.38 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $50.33 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $50.33 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $39.31 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $34.64 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $34.19 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $34.19 | 2 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $21.37 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $19.34 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $16.87 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $16.87 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 68 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 69 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
69 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
69 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
68 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 748 | 118 |
| Eliquis | Apixaban | 459 | 57 |
| Gabapentin | Gabapentin | 450 | 64 |
| Amlodipine Besylate | Amlodipine Besylate | 358 | 76 |
| Memantine Hcl | Memantine Hcl | 289 | 42 |
| Levothyroxine Sodium | Levothyroxine Sodium | 278 | 43 |
| Lisinopril | Lisinopril | 271 | 27 |
| Donepezil Hcl | Donepezil Hcl | 267 | 35 |
| Metoprolol Succinate | Metoprolol Succinate | 256 | 20 |
| Tamsulosin Hcl | Tamsulosin Hcl | 255 | 37 |
| Losartan Potassium | Losartan Potassium | 248 | 53 |
| Pantoprazole Sodium | Pantoprazole Sodium | 244 | 49 |
| Sertraline Hcl | Sertraline Hcl | 218 | 24 |
| Omeprazole | Omeprazole | 207 | 29 |
| Metformin Hcl | Metformin Hcl | 192 | 37 |
| Furosemide | Furosemide | 185 | 44 |
| Metoprolol Tartrate | Metoprolol Tartrate | 165 | 39 |
| Trazodone Hcl | Trazodone Hcl | 165 | 24 |
| Carvedilol | Carvedilol | 152 | 24 |
| Quetiapine Fumarate | Quetiapine Fumarate | 148 | 28 |
| Famotidine | Famotidine | 146 | 32 |
| Clopidogrel | Clopidogrel Bisulfate | 142 | 20 |
| Potassium Chloride | Potassium Chloride | 137 | 28 |
| Finasteride | Finasteride | 136 | 16 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 135 | 25 |
| Simvastatin | Simvastatin | 122 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 121 | 19 |
| Tradjenta | Linagliptin | 119 | suppressed |
| Mirtazapine | Mirtazapine | 113 | 32 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 93 | 18 |
| Hydralazine Hcl | Hydralazine Hcl | 88 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 86 | 14 |
| Divalproex Sodium | Divalproex Sodium | 85 | 15 |
| Januvia | Sitagliptin Phosphate | 80 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 77 | suppressed |
| Risperidone | Risperidone | 70 | 17 |
| Jardiance | Empagliflozin | 69 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 69 | suppressed |
| Gemtesa | Vibegron | 68 | suppressed |
| Latanoprost | Latanoprost | 67 | 18 |
| Hydrochlorothiazide | Hydrochlorothiazide | 66 | 12 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 65 | 26 |
| Tramadol Hcl | Tramadol Hcl | 63 | 23 |
| Aripiprazole | Aripiprazole | 62 | suppressed |
| Olanzapine | Olanzapine | 61 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 57 | 26 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 57 | 12 |
| Lorazepam | Lorazepam | 56 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 56 | suppressed |
| Rexulti | Brexpiprazole | 56 | suppressed |
| Atenolol | Atenolol | 54 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 54 | 12 |
| Amiodarone Hcl | Amiodarone Hcl | 52 | suppressed |
| Lidocaine | Lidocaine | 51 | 14 |
| Levetiracetam | Levetiracetam | 50 | suppressed |
| Allopurinol | Allopurinol | 48 | 11 |
| Midodrine Hcl | Midodrine Hcl | 47 | 11 |
| Venlafaxine Hcl | Venlafaxine Hcl | 45 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 44 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 43 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 43 | suppressed |
| Bupropion Xl | Bupropion Hcl | 42 | suppressed |
| Felodipine Er | Felodipine | 41 | suppressed |
| Xarelto | Rivaroxaban | 39 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 38 | 22 |
| Citalopram Hbr | Citalopram Hydrobromide | 37 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 36 | 12 |
| Montelukast Sodium | Montelukast Sodium | 33 | 11 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 32 | 21 |
| Nifedipine Er | Nifedipine | 32 | suppressed |
| Timolol Maleate | Timolol Maleate | 32 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 31 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 29 | suppressed |
| Humulin R | Insulin Regular, Human | 29 | suppressed |
| Levalbuterol Hcl | Levalbuterol Hcl | 29 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 28 | suppressed |
| Spironolactone | Spironolactone | 28 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 28 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 27 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 26 | suppressed |
| Valsartan | Valsartan | 26 | suppressed |
| Digoxin | Digoxin | 25 | suppressed |
| Ozempic | Semaglutide | 25 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 25 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 25 | 14 |
| Baclofen | Baclofen | 24 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 23 | suppressed |
| Pentoxifylline | Pentoxifylline | 23 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 22 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 22 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 21 | 12 |
| Calcium Acetate | Calcium Acetate | 20 | suppressed |
| Lactulose | Lactulose | 20 | 12 |
| Lansoprazole | Lansoprazole | 20 | suppressed |
| Meloxicam | Meloxicam | 19 | suppressed |
| Methocarbamol | Methocarbamol | 19 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 18 | 11 |
| Lurasidone Hcl | Lurasidone Hcl | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | suppressed |
| Prednisone | Prednisone | 18 | suppressed |
| Sucralfate | Sucralfate | 18 | suppressed |
| Dutasteride | Dutasteride | 17 | suppressed |
| Methadone Hcl | Methadone Hcl | 17 | suppressed |
| Cephalexin | Cephalexin | 16 | 14 |
| Brimonidine Tartrate | Brimonidine Tartrate | 15 | suppressed |
| Budesonide | Budesonide | 15 | suppressed |
| Colchicine | Colchicine | 15 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 15 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 15 | suppressed |
| Humalog | Insulin Lispro | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 15 | suppressed |
| Sevelamer Hcl | Sevelamer Hcl | 15 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Bumetanide | Bumetanide | 14 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Heparin Sodium | Heparin Sodium,porcine | 14 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 14 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 14 | suppressed |
| Movantik | Naloxegol Oxalate | 14 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 14 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 14 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 13 | suppressed |
| Pregabalin | Pregabalin | 13 | suppressed |
| Valproic Acid | Valproic Acid | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | suppressed |
| Azithromycin | Azithromycin | 12 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Galantamine Er | Galantamine Hbr | 12 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 12 | suppressed |
| Creon | Lipase/Protease/Amylase | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Methimazole | Methimazole | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,040.43 · 48 records | Ardelyx, Inc. | AIRSUPRA, BREZTRI, CAPVAXIVE, GARDASIL 9, GEMTESA, IBSRELA, JARDIANCE, Kerendia, LEQVIO, MOUNJARO, OTEZLA, Ozempic, PANCREAZE, REPATHA, Rybelsus, TRELEGY ELLIPTA, Tymlos, Veozah, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Gemtesa play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error